ClinicalTrials.gg

Program

baxdrostat

Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.

Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.

Furthest: phase 3, since Sep 6, 202326 company-led studies, 6 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca256 open or runningphase 3since Sep 6, 2023Aug 17, 2020Dec 10, 2026phase 2 · NCT07222917
Hoffmann-La Roche10 open or runningphase 1since Nov 20, 2013Nov 20, 2013none ahead

Also a collaborator on its studies: tigermed-consulting-co-ltd and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Nov 20, 2013.

  1. Jul 3, 20234 phase 1 studies in HypertensionAstraZeneca · NCT05963009, NCT05961397, NCT05961384 and 1 more
  2. Sep 6, 2023Phase 3 study in HypertensionAstraZeneca · NCT06034743 · 796 enrolled · United States, Argentina, Australia and more
  3. Dec 5, 2023Phase 3 study in HypertensionAstraZeneca · NCT06168409 · 218 enrolled · United States, Argentina, Australia and more
  4. Dec 21, 2023Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06194032 · 28 enrolled · Germany
  5. Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
  6. Mar 22, 2024Phase 2 study in Uncontrolled HypertensionAstraZeneca · NCT06336356 · 48 enrolled · United States
  7. Mar 27, 2024Phase 3 study in HypertensionAstraZeneca · NCT06344104 · 326 enrolled · Argentina, Australia, China and more
  8. Apr 5, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06357520 · 14 enrolled · United States
  9. Oct 23, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06657105 · 22 enrolled · United States
  10. Nov 5, 2024Phase 3 study in Heart FailureAstraZeneca · NCT06677060 · 11,300 planned · United States, Argentina, Australia and more
  11. Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06742723 · 5,000 planned · United States, Argentina, Australia and more
  12. May 16, 2025Phase 3 study in HyperaldosteronismAstraZeneca · NCT07007793 · 212 enrolled · United States, Australia, Canada and more
  13. Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
  14. May 22, 2026Phase 3 study in Uncontrolled HypertensionAstraZeneca · NCT07686120 · 286 planned · China

Ahead

  1. Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917
  2. Jul 27, 2027Primary completion: phase 3 study in HyperaldosteronismAstraZeneca · NCT07007793
  3. Feb 9, 2028Primary completion: phase 3 study in Uncontrolled HypertensionAstraZeneca · NCT07686120
  4. Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07686120Uncontrolled Hypertension · China3RecruitingAstraZenecaFeb 9, 2028286
NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more2Active, not recruitingAstraZenecaDec 10, 2026222
NCT07007793Hyperaldosteronism · United States, Australia, Canada and more3Active, not recruitingAstraZenecaJul 27, 2027212
NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 18, 20295,000
NCT06677060Heart Failure · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 17, 202911,300
NCT06657105Healthy Participants · United States1CompletedAstraZenecaFeb 3, 202522
NCT06357520Healthy Participants · United States1CompletedAstraZenecaJun 17, 202414
NCT06344104Hypertension · Argentina, Australia, China and more3CompletedAstraZenecaNov 24, 2025326
NCT06336356Uncontrolled Hypertension · United States2CompletedAstraZenecaDec 4, 202448
NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaFeb 24, 20282,554
NCT06194032Healthy Participants · Germany1CompletedAstraZenecaMay 13, 202428
NCT06168409Hypertension · United States, Argentina, Australia and more3CompletedAstraZenecaAug 17, 2025218
NCT06034743Hypertension · United States, Argentina, Australia and more3CompletedAstraZenecaMay 21, 2025796
NCT05966324Hypertension · United States1CompletedAstraZenecaSep 20, 202241
NCT05963009Hypertension · United States1CompletedAstraZenecaApr 29, 202014
NCT05961397Hypertension · United States1CompletedAstraZenecaApr 15, 202220
NCT05961384Hypertension · United States1CompletedAstraZenecaJan 15, 20228
NCT05526690Hypertension · United States1CompletedAstraZenecaDec 12, 202027
NCT05500820Hypertension · United States1CompletedAstraZenecaApr 3, 202056
NCT05470725Hypertension · United States1CompletedAstraZenecaApr 30, 202133
NCT05432167Renal Insufficiency, Chronic · United States2CompletedAstraZenecaMay 2, 2024195
NCT05459688Hypertension · United States2CompletedAstraZenecaNov 7, 2023175
NCT05137002Uncontrolled Hypertension · United States2CompletedAstraZenecaSep 13, 2022249
NCT04605549Hyperaldosteronism · United States2CompletedAstraZenecaOct 28, 202415
NCT04519658Resistant Hypertension · United States2CompletedAstraZenecaJun 14, 2022275
NCT01995383Atherosclerosis · United States1CompletedHoffmann-La RocheJun 201488

How it is read

Names in the registry

  • “Baxdrostat”, 8 entries
  • “CIN-107”, 7 entries
  • “Baxdrostat/dapagliflozin”, 3 entries
  • “baxdrostat”, 3 entries
  • “RO6836191”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.